Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11540981 | BIOFRONTERA | Nanoemulsion formulation with improved stability and cell penetration |
Feb, 2028
(3 years from now) | |
US11235169 | BIOFRONTERA | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device |
Oct, 2040
(16 years from now) |
Market Authorisation Date: 10 May, 2016
Treatment: Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminat...
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11077192 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
US11571478 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
US11135293 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
US10357567 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
US11690914 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) |
Market Authorisation Date: 03 December, 1999
Treatment: Treatment of actinic keratoses of upper extremities by photodynamic therapy
Dosage: SOLUTION;TOPICAL